Part of the B -category B pharmaceutical stocks in Hong Kong stocks are strong, and Hang Seng Medical ETF (513060) premiums are significantly premium

Part of the B -type pharmaceutical stocks in Hong Kong stocks strengthened, Yongtai Bio rose more than 25%, and Lepu Bio rose more than 15%.Hang Seng Medical ETF (513060) fell 1.67%, with a significant premium, a premium of 1.07%, a turnover of 90 million, or a good time for layout.

As of September 9, 2022, the PE (TTM) of the pharmaceutical biological sector was 22.85 times, and the number of points reached 0.50%of 10 years.Since September 2020, the valuation of the pharmaceutical industry has continued to be adjusted. Medical equipment, medical services, biological products, Chinese medicine, chemical pharmaceutical, and pharmaceutical business sectors 10 (2012- to this day) are 0.3%, 0.3%, 0.5%, and 0.5%, respectively, and 0.5%, and 0.5%, and 0.5%, and 0.5%, and 0.5%, and 0.5%, and 0.5%, and 0.5%.3.2%, 4.1%, 13.6%, 33.5%.

Wanhe Securities said that based on the poor performance of the medical industry in the first half of the year and the current price -earnings ratio of the current low level, high -quality tracks with both growth and certainty will welcome Davis.The main investment direction suggestions are as follows: Water selling people in innovative research and development industry chain -CXO companies with gradually improve industry chain: In the context of accelerating the transfer of the global pharmaceutical industry and the wave of domestic innovative drugs, the industry's prosperity continues to rise, and its performance is expected to maintain a high speed.increase.

- END -